Bio-Gene Technology Limited announced Mr. James Joughin indicated that due to increasing commitments associated with his Chairmanship and director roles on other ASX-listed and private companies, his intention was to retire from the Bio-Gene Board effective 30 June 2023. James has now advised that given his workload on other companies has increased significantly he will leave the Bio-Gene Board to concentrate on these other activities, effective immediately. Dr. Peter Beetham has advised that he too will be stepping down from the Board, effective immediately, to concentrate on his executive role at Cibus, following the definitive merger agreement of Calyxt with Cibus.

The new company, following the merger close, will require him to take on a lead role in the combination of two leading companies in the Agricultural Gene Editing industry. The Company has appointed Peter to Scientific Advisory Board, joining Professor Cate Hill from Purdue University. Mr. Richard Jagger, Managing Director and CEO of Bio-Gene, has formerly advised the Board that he wishes to allow for an orderly transition within the Company, that will see him step down as CEO to a supporting role focused on stakeholder management of Bio-Gene's existing and future development partnership relationships.

The timing of this transition will be confirmed over coming months.